Sustainability and ESG Report

The report describes LEO Pharma's 2022 sustainability progress, including SBTi approval of its Scope 1, 2 and 3 climate targets and a 91% renewable-electricity share. It reports reduced Scope 1 and 2 emissions against the 2019 baseline and describes continuing work on energy efficiency and supplier engagement. The report also documents sustainability oversight by the Global Leadership Team and progress on the company's responsible-business programs.